Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-25
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic ureminc syndrome (aHUS).